A low molecular weight dextran sulphate, ILB ®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial
Research output: Contribution to journal › Article › peer-review
124Downloads
(Pure)
Fingerprint
Dive into the research topics of 'A low molecular weight dextran sulphate, ILB ®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial'. Together they form a unique fingerprint.
Keyphrases
Pharmacology, Toxicology and Pharmaceutical Science